Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

23.73 USD -0.05 (-0.23%)
Official Closing Price Updated: 7:49 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Exelixis Inc

< Previous 1 2 3 4 5 6 7 8 9
...
79 80 Next >
Notable Monday Option Activity: ADI, EXEL, KBH
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Analog Devices Inc (ADI), where a total volume of 11,041 contracts has been traded... 
Tags Stocks
From Market News Video
Good News, Bad News Day
Today the stock market woke up to the risks both political and economic facing the Land of the Free and the Home of the Brave after reflecting over the weekend. 
Tags Stocks / Equities
From Blogs - TalkMarkets
Exelixis Announces Preliminary Fourth Quarter and Full Year 2020 Financial Results, Provides 2021 Financial Guidance, and Outlines Key Priorities and Anticipated Milestones For 2021
Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fourth quarter and full year 2020, provided financial guidance for full year 2021, and delivered an... 
From Business Wire News Releases
3 Top Biotech Picks for 2021
One big biotech and two small biotechs that share a common denominator: Great growth prospects. 
Tags NVAX EXEL BMY
From Motley Fool
5 Value Stocks That Will Make You Richer in 2021
Bargains are plentiful for value investors in the new year. 
Tags EXEL Market News WBA
From Motley Fool
Interesting EXEL Put And Call Options For March 19th
Investors in Exelixis Inc (EXEL) saw new options begin trading today, for the March 19th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time... 
Tags Stocks
From Market News Video
Exelixis to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021
Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the virtual 39th Annual J.P.... 
From Business Wire News Releases
Why Calithera Biosciences Stock Is Plunging Today
The company reported negative results from a clinical trial. 
Tags EXEL Market News CALA
From Motley Fool
3 Healthcare Stocks That Are Screaming Buys in 2021
Here's your prescription for huge returns in the upcoming year. 
Tags EXEL JUSHF Market News
From Motley Fool
Should Investors Be Watching These Top Biotech Stocks Next Week? 3 To Consider
Tags Market News
From Stockmarket.com
3 Beaten-Down Growth Stocks That Can Soar in 2021
These high-growth companies are big-time bargains for opportunistic investors. 
Tags VRTX PING Market News
From Motley Fool
Should Investors Consider This Biotech Takeover Target?
Getting in on the extensive merger and acquisition game of large pharmaceutical companies is the ultimate endgame for Exelixis, a biotech that already boasts an established cancer-focused product... 
Tags LLY NVS ALXN
From Motley Fool
Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Differentiated Thyroid C
Exelixis, Inc. (NASDAQ: EXEL) today announced that COSMIC-311, the phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) versus placebo in patients with radioiodine-refractory differentiated... 
From Business Wire News Releases
3 Top Biotech Stocks to Buy Right Now
Each of them should enjoy strong sales growth in 2021 and beyond. 
Tags NVAX EXEL BMY
From Motley Fool
XWPharma Names Michael M. Morrissey, PhD to Board of Directors
Appointment Adds Senior Biopharma Operational Expertise to Board Oversight as Company Advances its Pipeline of Novel CNS Therapeutics in Research and Clinical Development 
From GlobeNewswire News Releases
No Security
Value Line, which usually says to buy recommended stocks for growth and income, caused a shock wave today. 
Tags Stocks / Equities
From Blogs - TalkMarkets
Add Up The Parts: PBE Could Be Worth $77
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Pearl Harbor Day
With new corona-virus lockdowns, the price of oil has fallen. 
Tags Stocks / Equities
From Blogs - TalkMarkets
Exelixis In-Licenses Aurigene’s Novel CDK7 Inhibitor and Files Investigational New Drug Application for Phase 1 Clinical Trial in Advanced Solid Tumors
Exelixis, Inc. (Nasdaq: EXEL) and Aurigene today announced that Exelixis has exercised its exclusive option for Aurigene’s novel CDK7 inhibitor under the companies’ July 2019 agreement. Exelixis has... 
From Business Wire News Releases
Calithera Biosciences: An Under The Radar Opportunity
Calithera is a high-risk, high reward speculative investment addressing high unmet and under-served needs markets, with a lower bar data threshold to meet. Calithera has an important near-term catalyst... 
Tags Stocks / Equities Healthcare Pharma/Biotech
From Blogs - TalkMarkets
Sometimes Bad News Is Good
The horrible unemployment data today increases the odds that a renewed stimulus bill will be crafted before Biden takes the helm. 
Tags Stocks / Equities
From Blogs - TalkMarkets
Should Investors Buy Moderna Stock for Its Coronavirus Vaccine?
Don't forget about the biotech's long-term valuation. 
Tags Market News BMRN SGEN
From Motley Fool
Problems To Come
Perhaps the biggest risk for bulls is the likelihood of higher taxes on capital gains and inheritances being planned by the future Biden Administration. 
Tags Stocks / Equities
From Blogs - TalkMarkets
Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application
Exelixis, Inc. (Nasdaq: EXEL), Iconic Therapeutics, Inc. (Iconic) and Zymeworks Inc. (NYSE:ZYME) today announced that Exelixis has exercised its exclusive option for Iconic’s lead oncology... 
From Business Wire News Releases
Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) for the Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy
Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX®... 
From Business Wire News Releases
Got $50? 4 Smart Stocks to Buy Into Right Now
You don't need to start with a fortune to build wealth on Wall Street. 
Tags AUY SIRI Market News
From Motley Fool
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in December
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following virtual investor conferences in December: 
From Business Wire News Releases
EQAL's Holdings Imply 11% Gain Potential
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
12 Healthcare Stocks Moving In Thursday's After-Market Session
Gainers Chembio Diagnostics (NASDAQ:CEMI) shares moved upwards by 11.95% to $4.96 during Thursday's after-market session. ... 
Tags After/Hours Center CBAY Benzinga
From Benzinga
Exelixis Announces Third Quarter 2020 Financial Results and Provides Corporate Update
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2020 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
79 80 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.